Labcorp (LH) fundamentals: P/E, valuation, undervalued?
Labcorp · Health Care · ref. ETF XLV · price $313.64
In short — Labcorp trades at 25.9× earnings (P/E), 15.8× forward, with a net margin of 7.0 % and revenue growth of +6 %. Read: Cheap for the growth (P/E 16 for ~28% growth (PEG 0.6)).
Is Labcorp stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$313.64+12.1% over range
Oct 14, 25low $246.64 · high $339.34Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
75% recommend buying · 8 analysts
Valuation : Cheap for the growth — P/E 16 for ~28% growth (PEG 0.6)
Valuation
25.9
P/E (price/earnings)
15.8
Forward P/E
0.92
PEG
2.9
Price/book (P/B)
$25.4B
Market cap
12.09
EPS
Profitability & growth
7.0 %
Net margin
+6 %
Revenue growth
+28 %
Earnings growth
$6.8B
Total debt
Labcorp income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $14.9B | $1.3B | 8.6 % |
| 2023 | $12.2B | $418M | 3.4 % |
| 2024 | $13.0B | $746M | 5.7 % |
| 2025 | $14.0B | $877M | 6.3 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Labcorp's P/E and is the stock undervalued? What's a good P/E?
Labcorp's P/E is 25.9 (forward 15.8). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Labcorp profitable?
Labcorp has a net margin of 7.0 % (EPS 12.09). The company is profitable.
Is LH stock expensive?
Our read: "Cheap for the growth" — P/E 16 for ~28% growth (PEG 0.6). Cross-check with growth and sector.
💬 A question about Labcorp? The JPI assistant answers using our backtest data.